Literature DB >> 8031057

Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones.

N Dholakia1, K V Rolston, D H Ho, B LeBlanc, G P Bodey.   

Abstract

The antibacterial activity of levofloxacin was compared with those of ofloxacin and ciprofloxacin against bacterial isolates from patients with cancer. In general, levofloxacin was as active or was twofold more active than ofloxacin and was two- to fourfold less active than ciprofloxacin against most gram-negative pathogens. Against Pseudomonas aeruginosa, ciprofloxacin was the most active agent tested (MIC for 90% of isolates tested, 1.0 microgram/ml). Overall, all three agents had similar activities against gram-positive organisms and were moderately active against methicillin-susceptible Staphylococcus aureus and coagulase-negative staphylococci, Streptococcus species, and Enterococcus species.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8031057      PMCID: PMC284553          DOI: 10.1128/AAC.38.4.848

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  In vitro activity of Ro 23-9424, a dual-action antibacterial agent, against bacterial isolates from cancer patients compared with those of other agents.

Authors:  K V Rolston; H T Nguyen; D H Ho; B LeBlanc; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

2.  In vitro activity of DR-3355, an optically active ofloxacin.

Authors:  T Une; T Fujimoto; K Sato; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

3.  Norfloxacin for prevention of bacterial infections in granulocytopenic patients.

Authors:  D J Winston; W G Ho; R E Champlin; J Karp; J Bartlett; R S Finley; J H Joshi; G Talbot; L Levitt; S Deresinski
Journal:  Am J Med       Date:  1987-06-26       Impact factor: 4.965

4.  Intravenous ciprofloxacin for infections in cancer patients.

Authors:  K V Rolston; E Haron; C Cunningham; G P Bodey
Journal:  Am J Med       Date:  1989-11-30       Impact factor: 4.965

5.  In vitro antibacterial activity of DR-3355, the S-(-)-isomer of ofloxacin.

Authors:  T Fujimoto; S Mitsuhashi
Journal:  Chemotherapy       Date:  1990       Impact factor: 2.544

6.  Synergy of levofloxacin (L-ofloxacin) and oxacillin against quinolone-resistant Staphylococcus aureus, measured by the time-kill method.

Authors:  J A Patel; C T Pachucki; J R Lentino
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

7.  Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin.

Authors:  A W Dekker; M Rozenberg-Arska; J Verhoef
Journal:  Ann Intern Med       Date:  1987-01       Impact factor: 25.391

8.  In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin.

Authors:  K P Fu; S C Lafredo; B Foleno; D M Isaacson; J F Barrett; A J Tobia; M E Rosenthale
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

9.  Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients.

Authors:  J P Flaherty; D Waitley; B Edlin; D George; P Arnow; P O'Keefe; R A Weinstein
Journal:  Am J Med       Date:  1989-11-30       Impact factor: 4.965

10.  Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients.

Authors:  C C Chan; B A Oppenheim; H Anderson; R Swindell; J H Scarffe
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

View more
  14 in total

1.  Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus.

Authors:  J M Entenza; J Vouillamoz; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Impact of a fluoroquinolone formulary change on acquisition of quinolone-resistant gram-negative bacilli.

Authors:  B N Hota; S Pur; L Phillips; R A Weinstein; J Segreti
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-06       Impact factor: 3.267

3.  Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies.

Authors:  S Bajaksouzian; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

4.  Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods.

Authors:  M A Visalli; S Bajaksouzian; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

5.  Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid.

Authors:  J Child; D Mortiboy; J M Andrews; A T Chow; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

Review 6.  Ofloxacin otic solution: a review of its use in the management of ear infections.

Authors:  K L Simpson; A Markham
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

7.  Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem.

Authors:  S K Spangler; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

8.  In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to four fluoroquinolones (levofloxacin, d-ofloxacin, ofloxacin, and ciprofloxacin), cefpirome, and meropenem.

Authors:  J E Hoppe; E Rahimi-Galougahi; G Seibert
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 9.  Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.

Authors:  H D Langtry; H M Lamb
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

Review 10.  In vitro activity of fluoroquinolones against gram-positive bacteria.

Authors:  G M Eliopoulos
Journal:  Drugs       Date:  1995       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.